Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Genetics and Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration due to dystrophin deficiency.
• Current treatments for DMD are limited, highlighting the need for innovative therapeutic strategies.
• Cell therapy using muscle stem cells (MuSCs) offers a promising avenue for restoring muscle function in DMD patients.

Purpose of the Study:

• To develop a method for generating fetal-like MuSCs from human induced pluripotent stem cells (iPSCs).
• To assess the potential of these iPSC-derived MuSCs for Duchenne muscular dystrophy (DMD) cell therapy.
• To evaluate the muscle regeneration capacity and dystrophin production of these cells in vivo.

Main Methods:

• Human induced pluripotent stem cells (iPSCs) were differentiated into muscle stem cells (MuSCs) with monitoring of MYF5 expression.
• Gene expression profiling was used to characterize cells at different differentiation stages.
• Transplantation of late-stage MYF5-positive cells into Duchenne muscular dystrophy (DMD) model mice was performed to assess in vivo efficacy.

Main Results:

• MYF5-positive cells in the late differentiation stage exhibited fetal MuSC characteristics.
• These late-stage cells demonstrated significant muscle regeneration potential in DMD model mice.
• Transplanted cells successfully produced dystrophin in vivo, leading to muscle function recovery and generation of PAX7-positive MuSC-like cells.

Conclusions:

• A novel differentiation method successfully generated fetal-like MuSCs from iPSCs.
• Late-stage MYF5-positive iPSC-derived MuSCs possess the potential for effective cell therapy in Duchenne muscular dystrophy.
• These findings pave the way for developing new treatments for DMD using patient-derived stem cells.